Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, is on a mission to develop and market breakthrough product candidates for the treatment of central nervous system diseases. The company's lead product candidate, the roluperidone (MIN-101), is currently being assessed for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. has also developed the MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has recently submitted its New Drug Application (NDA) for the roluperidone and entered into a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally, excluding Asia. Since its inception in 2007, Minerva Neurosciences, Inc. has undergone several changes, including a name change from Cyrenaic Pharmaceuticals, Inc. in 2013, before settling its headquarters in Waltham, Massachusetts.
Minerva Neurosciences's ticker is NERV
The company's shares trade on the NASDAQ stock exchange
They are based in Waltham, Massachusetts
There are 11-50 employees working at Minerva Neurosciences
It is minervaneurosciences.com
Minerva Neurosciences is in the Healthcare sector
Minerva Neurosciences is in the Biotechnology industry
The following five companies are Minerva Neurosciences's industry peers: